Blueprint Medicines announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease.
Blueprint Medicines will apply its kinase-focused drug discovery platform to identify and optimize drug candidates and will conduct all research activities prior to the filing of an Investigational New Drug (IND) application with the Food and Drug Administration.
|Searching for more deal information? Current Partnering offers the following options:
Alexion will be responsible for the development and commercialization of these Blueprint Medicines' drug candidates under the collaboration.
Blueprint Medicines will receive an upfront payment of $15 million and will be reimbursed for all research expenses.
Blueprint Medicines is eligible to receive over $250 million in payments upon the successful achievement of pre-specified preclinical, clinical, regulatory and commercial milestones.
Blueprint Medicines will be eligible to receive royalty payments following the commercialization of the product.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies